AttgeNO — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Attgeno is a clinical-stage biotech leveraging a proprietary nitric oxide-donating platform to develop targeted therapies for acute pulmonary hypertension and other conditions. The company has recently completed a Phase IIa study for its lead candidate, Supernitro, in post-cardiac surgery aPH patients. Its leadership team includes world-renowned NO experts and veterans from successful companies like Aerocrine and Actelion, providing deep experience in both the science and commercialization of pulmonary hypertension treatments.

CardiovascularPulmonary

Technology Platform

Proprietary 'Supernitro' platform for targeted, organ-specific delivery of nitric oxide (NO).

Opportunities

The lead candidate, Supernitro, addresses a high-mortality condition with significant unmet need in acute pulmonary hypertension, particularly post-cardiac surgery.

The proprietary NO-delivery platform also offers potential for expansion into other cardiovascular and pulmonary diseases where targeted vasodilation is beneficial, creating a pipeline-in-a-product opportunity.

Risk Factors

The company faces clinical risk from a very small Phase IIa dataset and high dependency on a single lead candidate.

Significant financing is required for costly late-stage trials, and the competitive landscape in pulmonary hypertension is crowded with large, well-resourced players.

Competitive Landscape

Attgeno competes in the pulmonary hypertension space, which includes large pharma companies with approved therapies for chronic PH (e.g., Johnson & Johnson/Actelion, United Therapeutics) and providers of inhaled NO systems (e.g., Mallinckrodt's INOmax). Its key differentiation is the promise of a targeted, potentially more convenient intravenous drug versus the established but cumbersome inhaled NO therapy.

More companies in Sweden →